Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, evaluating the investigational therapy ...

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

On September 9, Seema Shah, Chief Global Strategist at Principal Asset Management, appeared on CNBC for an interview to ...